新华财经北京6月10日电近日,辉瑞公布其GLP-1受体激动剂埃诺格鲁肽(先维盈®)与诺和诺德司美格鲁肽(诺和盈®)的头对头研究——SLIMMER-UP-SWITCH的20周中期分析结果,显示埃诺格鲁肽在减重数值上略优于司美格鲁肽。不过,业内人士指出,一项II期、开放标签、小样本的中期分析尚不足以撼动司美格鲁肽近十年建立的商业护城河,真正的GLP-1市场变局,仍需等待双方更大规模、更长期的III期...
Source Link新华财经北京6月10日电近日,辉瑞公布其GLP-1受体激动剂埃诺格鲁肽(先维盈®)与诺和诺德司美格鲁肽(诺和盈®)的头对头研究——SLIMMER-UP-SWITCH的20周中期分析结果,显示埃诺格鲁肽在减重数值上略优于司美格鲁肽。不过,业内人士指出,一项II期、开放标签、小样本的中期分析尚不足以撼动司美格鲁肽近十年建立的商业护城河,真正的GLP-1市场变局,仍需等待双方更大规模、更长期的III期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.